Exelixis, Inc. (Nasdaq: EXEL) has recently submitted an investigational new drug (IND) application to the USFDA for its candidate anticancer compound XL147.
XL147 is a novel, orally available small molecule that selectively inhibits the activity of phosphoinositide-3 kinase (PI3K). In human tumors, activation of PI3K is frequent – thereby promoting tumor cell growth, survival, and resistance to chemotherapy and radiotherapy.
According to Gisela M. Schwab, MD, senior vice president and chief medical officer at Exelixis:
"A growing body of data indicates that inappropriate activation of the PI3K signaling pathway is a common feature of human tumors and may result from dysregulation at multiple points along the signaling cascade. We are therefore evaluating multiple compounds that inhibit distinct components of the PI3K pathway. XL147 potently and selectively inhibits PI3K.
Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics cancer treatment and for treatment of other serious diseases.
Find more details from the press release.
Comment Preview